Avid Bioservices Inc (CDMO)

[freethemice]

The dosing is weekly in these trials. The concentration of bavi needs to be maintained during treatment,
and I think the half-life (time to get to 50% of initial concentration) is about a week. If the patient enters monotherapy
with bavi it is still given weekly. They will have to do more studies to really know whether the monotherapy is
needed, or for how long, in those patients that continue to live. It could be that at some point these
patients have developed immunity to their cancer and so could stop, but all that is speculation for now. It was
shown in the rat study with glioma that 13% of them survived and had developed immunity.